TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

T. Facon; S. K. Kumar; T. Plesner; P. Moreau; N. Bahlis; H. Goldschmidt; M. O’Dwyer; A. Perrot; C. P. Venner; K. Weisel; J. R. Mace; N. Raje; M. Tiab; M. Macro; L. Frenzel; X. Leleu; H. Pei; F. Borgsten; S. Z. Usmani

doi:10.1097/01.hs9.0000846612.13339.9e

TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

T. Facon, S. K. Kumar, T. Plesner, P. Moreau, N. Bahlis, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. P. Venner, K. Weisel, J. R. Mace, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, F. Borgsten, S. Z. Usmani

Janssen-Cilag, Birkerød, Denmark.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	P936
Tidsskrift	HemaSphere
Vol/bind	6
Udgave nummer	Suppl. 3
Sider (fra-til)	826-827
ISSN	2572-9241
DOI	https://doi.org/10.1097/01.hs9.0000846612.13339.9e
Status	Udgivet - 2022
Begivenhed	EHA 2022 Hybrid Congress - Vienna, Østrig Varighed: 9. jun. 2022 → 12. jun. 2022

Konference

Konference	EHA 2022 Hybrid Congress
Land/Område	Østrig
By	Vienna
Periode	09/06/2022 → 12/06/2022

Dokumenter og links

10.1097/01.hs9.0000846612.13339.9eLicens: CC BY-NC-ND

Citationsformater

Facon, T., Kumar, S. K., Plesner, T., Moreau, P., Bahlis, N., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Borgsten, F., & Usmani, S. Z. (2022). TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. HemaSphere, 6(Suppl. 3), 826-827. [P936]. https://doi.org/10.1097/01.hs9.0000846612.13339.9e

@article{caf1df89ee344669af41153588bc9943,

title = "TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY",

author = "T. Facon and Kumar, {S. K.} and T. Plesner and P. Moreau and N. Bahlis and H. Goldschmidt and M. O{\textquoteright}Dwyer and A. Perrot and Venner, {C. P.} and K. Weisel and Mace, {J. R.} and N. Raje and M. Tiab and M. Macro and L. Frenzel and X. Leleu and H. Pei and F. Borgsten and Usmani, {S. Z.}",

year = "2022",

doi = "10.1097/01.hs9.0000846612.13339.9e",

language = "English",

volume = "6",

pages = "826--827",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "Suppl. 3",

note = "EHA 2022 Hybrid Congress ; Conference date: 09-06-2022 Through 12-06-2022",

}

Facon, T, Kumar, SK, Plesner, T, Moreau, P, Bahlis, N, Goldschmidt, H, O’Dwyer, M, Perrot, A, Venner, CP, Weisel, K, Mace, JR, Raje, N, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Pei, H, Borgsten, F & Usmani, SZ 2022, 'TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY', HemaSphere, bind 6, nr. Suppl. 3, P936, s. 826-827. https://doi.org/10.1097/01.hs9.0000846612.13339.9e

TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. / Facon, T.; Kumar, S. K.; Plesner, T. et al.

I: HemaSphere, Bind 6, Nr. Suppl. 3, P936, 2022, s. 826-827.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

AU - Facon, T.

AU - Kumar, S. K.

AU - Plesner, T.

AU - Moreau, P.

AU - Bahlis, N.

AU - Goldschmidt, H.

AU - O’Dwyer, M.

AU - Perrot, A.

AU - Venner, C. P.

AU - Weisel, K.

AU - Mace, J. R.

AU - Raje, N.

AU - Tiab, M.

AU - Macro, M.

AU - Frenzel, L.

AU - Leleu, X.

AU - Pei, H.

AU - Borgsten, F.

AU - Usmani, S. Z.

PY - 2022

Y1 - 2022

U2 - 10.1097/01.hs9.0000846612.13339.9e

DO - 10.1097/01.hs9.0000846612.13339.9e

M3 - Conference abstract in journal

SN - 2572-9241

VL - 6

SP - 826

EP - 827

JO - HemaSphere

JF - HemaSphere

IS - Suppl. 3

M1 - P936

T2 - EHA 2022 Hybrid Congress

Y2 - 9 June 2022 through 12 June 2022

ER -